S'abonner

Fungal disease incidence and prevalence in Iraq – Preliminary estimates - 08/11/24

Doi : 10.1016/j.mycmed.2024.101516 
Karzan A. Mohammad a, Hero M. Ismail a, Khattab A.M. Shekhany b, Raya Kh. Yashooa c, Delan A. Younus d, Samir Kh. Abdullah e, Azhar A.F. Alatraqchi f, Rasool Aldabbagh c, David W. Denning g,
a Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Iraq 
b Biology Department, College of Science, University of Sulaimani, Sulaimani, Iraq 
c General Directorate of Scientific Research Center, Salahaddin University-Erbil, Erbil, 44001, Kurdistan, Iraq 
d Department of Medical Microbiology, College of Medicine, University of Duhok, Duhok, Iraq 
e Department of Medical Laboratory Technology, Alnoor University College, Nineva, Iraq 
f Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq 
g Manchester Fungal Infection Group, The University of Manchester and Manchester Academic Health Science Centre, Manchester, UK 

Corresponding author at: Professor of Infectious Diseases in Global Health, Manchester Fungal Infection Group, CTF building, Grafton Street, Manchester, M13 9NT, UK.Professor of Infectious Diseases in Global HealthManchester Fungal Infection GroupCTF building, Grafton StreetManchesterM13 9NTUK

Highlights

Compute and estimate the prevalence and burden of fungal infections in Iraq.
Recurrent Candida vaginitis, fungal rhinosinusitis, and tinea capitis are probably the most frequent fungal diseases in Iraq.
Respiratory fungal diseases and mucormycosis are also disproportinately common compared with many countries.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

The surveillance of serious and superficial skin fungal infections in Iraq has not been conducted. Limited information exists on their incidence and prevalence.

Objectives

This study aimed to analyze, compute and estimate the prevalence and burden of fungal infections, as no previous data is available and no studies has been attempted in Iraq.

Methods

In the present study the data were collected and reviewed from published data on epidemiology of fungal infections nationally, internationally, from unpublished postgraduate master and PhD theses, hospital records and private clinic records. External sources of data from other countries were used for diseases which lacked sufficient local data.

Results

We estimated 985,628 annual serious infections comprising of 2.26 % of the total population. When including superficial fungal infections group of the skin, this rises to 2,075,113 infections at 4.76 % of the total population. The most common serious and skin infections were recurrent Candida vaginitis, fungal rhinosinusitis and tinea capitis comprising 61.5 %, 21.8 %, and 22.4 % of all infections although the total incidence of superficial fungal infections was also high at 1,071,485. Respiratory fungal disease is also common comprising 14.0 % of infections. We predicted the following annual burden per 100,000; oral candidiasis at 247.9, esophageal candidiasis at 6.04, candidemia at 5.0, Candida peritonitis at 0.75, recurrent Candida vaginitis at 5461, allergic bronchopulmonary aspergillosis at 35, severe asthma with fungal sensitisation at 46, invasive aspergillosis at 7.9, chronic pulmonary aspergillosis at 11.7, chronic fungal rhinosinusitis at 496, mucormycosis at 0.99, fungal keratitis at 14.0, and total dermatophytosis at 1631, the most severe being tinea capitis at 366. Many of these estimates were made with data sourced from other nations, so additional data from Iraq is required to validate or modify these estimates.

Conclusion

Recurrent Candida vaginitis, fungal rhinosinusitis, and tinea capitis are considered to be the most frequent fungal diseases present in Iraq.

Le texte complet de cet article est disponible en PDF.

Keywords : Candida vaginitis, Fungal rhinosinusitis, Tinea capitis, Aspergillosis, Asthma, Mucormycosis, Fungal keratitis


Plan


© 2024  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 34 - N° 4

Article 101516- décembre 2024 Retour au numéro
Article précédent Article précédent
  • Formulation and evaluation of herbal essential oil based nail lacquer for management of onychomycosis
  • Ravi Goyal, Annima Goyal, Azmat Ali Khan, Sabiha Fatima, Tanveer Singh, Deepinder Singh Malik
| Article suivant Article suivant
  • Laboratory practices for the diagnosis and management of mucormycosis in France, 2024
  • Laurence Millon, Françoise Botterel, Julie Bonhomme, Stéphane Valot, Philippe Poirier, Marie-Fleur Durieux, Jeanne Bigot, Guillaume Desoubeaux, Adélaïde Chesnais, Florent Morio, Marc Pihet, Kévin Brunet, Anne-Pauline Bellanger, Sébastien Imbert, Gilles Nevez, Solène Le Gal, Nathalie Bourgeois, Anne Debourgogne, Marjorie Cornu, Florence Persat, Lilia Hasseine, Marie-Elisabeth Bougnoux, Sophie Brun, Muriel Cornet, Loïc Favennec, Gilles Gargala, Christine Bonnal, Jean-Pierre Gangneux, Alexandre Alanio, Xavier Iriart, Caroline Mahinc, Taieb Chouaki, André Paugam, Valérie Letscher-Bru, Eric Dannaoui

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.